SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer - PR Newswire APAC - PR Newswire Asia

5/8/2022 12:00:00 AM2 years 11 months ago

  • SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
  • SCG101 is the first TCR-T cell therapy product to receive a multi-regional Investigational New Drug (IND)… [+6727 chars]

    full article...